Thrombocytopenia in the newborn

Current Opinion in Pediatrics

Volumn 15, Issue 1, 2003, Pages 17-23

  Roberts, Irene A G ^a   Murray, Neil A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOPOIETIC GROWTH FACTOR; INTERLEUKIN 11; THROMBOPOIETIN;

ALLOIMMUNITY; DISEASE CLASSIFICATION; EVIDENCE BASED MEDICINE; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NECROTIZING ENTEROCOLITIS; NEWBORN; NEWBORN SEPSIS; PERINATAL ASPHYXIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

AGE FACTORS; HUMANS; INFANT, NEWBORN; RISK FACTORS; THROMBOCYTOPENIA;

EID: 0037304497     PISSN: 10408703     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008480-200302000-00004     Document Type: Review

References (80)

1. Pahal G, Jauniaux E, Kinnon C, et al.: Normal development of human fetal hematopoiesis between eight and seventeen weeks' gestation. Am J Obstet Gynecol 2000, 183;1029-1034.
2. Holmberg L, Gustavii B, Jonsson A: A prenatal study of fetal platelet count and size with application to fetus at risk for Wiskott-Aldrich syndrome. J Pediatr 1983, 102:773-776.
3. Forestier F, Daffos F, Galacteros F, et al.: Hematological values of 163 normal fetuses between 18 and 30 weeks of gestation. Pediatr Res 1986, 20:342-346.
4. Forestier F, Daffos F, Catherine N, et al.: Developmental hematopoiesis in normal human fetal blood. Blood 1991, 77:2360-2363.
5. Hohlfeld P, Forestier F, Kaplan C, et al.: Fetal thrombocytopenia: a retrospective survey of 5,194 fetal blood samplings. Blood 1994, 84:1851-1856.
6. Burrows RF, Kelton JG: Incidentally detected thrombocytopenia in healthy mothers and their infants. N Engl J Med 1988, 319:142-145.
7. Sainio S, Jarvenpaa AL, Renlund M, et al.: Thrombocytopenia in term infants: a population-based study. Obstet Gynecol 2000, 95:441-446.
8. Castle V, Andrew M, Kelton J, et al.: Frequency and mechanism of neonatal thrombocytopenia. J Pediatr 1986, 108:749-755.
9. Mehta P, Vasa R, Neumann L, et al.: Thrombocytopenia in the high-risk infant. J Pediatr 1980, 97:791-794.
10. Murray NA, Roberts IA: Circulating megakaryocytes and their progenitors in early thrombocytopenia in preterm neonates. Pediatr Res 1996, 40:112-119.
11. Kahn DJ, Richardson DK, Billett HH: Association of thrombocytopenia and delivery method with intraventricular hemorrhage among very-low-birth-weight infants. Am J Obstet Gynecol 2002, 186:109-116.
12. Blajchman MA, Goldman M: Bacterial contamination of platelet concentrates: incidence, significance, and prevention. Semin Hematol 2001, 38(suppl 11):20-26. • This is a topical and comprehensive review of the incidence of bacterial contamination of platelet concentrates and the associated risks of platelet transfusion-associated septic episodes.
13. Kuehnert MJ, Roth VR, Haley NR, et al.: Transfusion-transmitted bacterial infection in the United States, 1998 through 2000. Transfusion 2001, 41:1493-1499.
14. 9/L, thrombocytopenic neonates receiving platelet transfusions had a higher mortality than neonates not given platelets, and hemorrhage was not the major contributing factor leading to death. This study provides the basis for developing controlled trials of platelet transfusion therapy in thrombocytopenic neonates.
15. Garcia MG, Duenas E, Sola MC, et al.: Epidemiologic and outcome studies of patients who received platelet transfusions in the neonatal intensive care unit. J Perinatol 2001, 21:415-420. • This paper describes a historic cohort study of neonates who received platelet transfusions over a 41-month period at a single hospital in Mexico City, Mexico. Despite the fact that complete records were available on fewer than 50% of the transfused babies, the findings of the study are very similar to those conducted in the United Kingdom (Murray et al. [14]) and U.S. (Del Vecchio et l. [16]) at around the same time. In particular, babies receiving platelet transfusions had a higher mortality than those who were not transfused (24.5% vs 3.7%), and the only reported hemorrhage was IVH, which is likely to have antedated the thrombocytopenia in the vast majority of babies.
16. Del Vecchio A, Sola MC, Theriaque DW, et al.: Platelet transfusions in the neonatal intensive care unit: factors predicting which patients will require multiple transfusions. Transfusion 2001, 41:803-808.
17. Roberts IAG, Murray NA: Thrombocytopenia in the newborn. In: Platelets. Michelson AD, ed. San Diego, CA: Academic Press; 2002:635-658.
18. Sola MC, Del Vecchio A, Rimsza LM: Evaluation and treatment of thrombocytopenia in the neonatal intensive care unit. Clin Perinatol 2000, 27:655-679.
19. Blanchette VS, Rand ML: Platelet disorders in newborn infants: diagnosis and management. Semin Perinatol 1997, 21:53-62.
20. Homans A: Thrombocytopenia in the neonate. Pediatr Clin North Am 1996, 43:737-756.
21. Sharif U, Kuban K: Prenatal intracranial hemorrhage and neurologic complications in alloimmune thrombocytopenia. J Child Neurol 2001, 16:838-842.
22. Murphy MF, Hambley H, Nicolaides K, et al.: Severe fetomaternal alloimmune thrombocytopenia presenting with fetal hydrocephalus. Prenat Diagn 1996, 16:1152-1155.
23. Stanworth SJ, Hackett GA, Williamson LM: Fetomaternal alloimmune thrombocytopenia presenting antenatally as hydrops fetalis. Prenat Diagn 2001, 21:423-424.
24. Radder CM, Brand A, Kanhai HH: A less invasive treatment strategy to prevent intracranial hemorrhage in fetal and neonatal alloimmune thrombocytopenia. Am J Obstet Gynecol 2001, 185:683-688. • This is the first report of a large population of patients (n=56) at risk for severe fetal alloimmune thrombocytopenia (as a result of a previously affected sibling) treated at a single center comparing the effects of invasive management (fetal blood sampling ± fetal platelet transfusion) with a noninvasive strategy (no fetal blood sampling). The eight pregnancies in which a previous sibling had suffered an ICH were managed invasively (fetal blood sampling ± fetal platelet transfusion and maternal IVIG) with a good outcome in all cases. The remaining 48 pregnancies (previous affected sibling had severe thrombocytopenia without ICH) were divided into 2 groups to assess the effects of invasive versus noninvasive treatment (maternal IVIG alone). No ICH was seen in either group, and the authors conclude that invasive management should be restricted to pregnancies in which previous sibling(s) suffered ICH.
25. Watts TL, Murray NA, Roberts IAG: Thrombopoietin has a primary role in the regulation of platelet production in preterm babies. Pediatr Res 1999, 46:28-32.
26. Mueller-Eckhardt C, Kiefel V, Grubert A, et al.: 348 cases of suspected neonatal alloimmune thrombocytopenia. Lancet 1989, 1:363-366.
27. Williamson LM, Hackett G, Rennie J, et al.: The natural history of fetomaternal alloimmunization to the platelet-specific antigen HPA-1 a (PIA1, Zwa) as determined by antenatal screening. Blood 1998, 92:2280-2287.
28. Davoren A, McParland P, Barnes CA, et al.: Neonatal alloimmune thrombocytopenia in the Irish population: a discrepancy between observed and expected cases. J Clin Pathol 2002, 55:289-292. • This is a large retrospective study over a 9-year period of the platelet serology laboratory records covering the whole of the Republic of Ireland. Only 27 verified cases of NAITP were identified in 18 families (1 in 16,500 live births), which is far below the expected incidence (1 in 1,000-1 in 2,000). This suggests that NAITP is underdiagnosed and that increased clinical awareness and possibly antenatal screening programs may be needed to avoid preventable deaths and disability due to severe thrombocytopenia.
29. Glade-Bender J, McFarland JG, Kaplan C, et al.: Anti-HPA-3A induces severe neonatal alloimmune thrombocytopenia. J Pediatr 2001, 138:862-867.
30. Kankirawatana S, Kupatawintu P, Juji T, et al.: Neonatal alloimmune thrombocytopenia due to anti-Nak(a). Transfusion 2001, 41:375-377.
31. Jallu V, Meunier M, Brement M, et al.: A new platelet polymorphism Duv(a+), localized within the RGD binding domain of glycoprotein Illa, is associated with neonatal thrombocytopenia. Blood 2002, 99:4449-4456.
32. De Tar MW, Klohe E, Grosset A, et al: Neonatal alioimmune thrombocytopenia with HLA alloimmunization: case report with immunohematologic and placental findings. Pediatr Dev Pathol 2002, 5:200-205.
33. Sasaki M, Yagihashi A, Kobayashi D, et al.: Neonatal alloimmune thrombocytopenia due to anti-human leukocyte antigen antibody: a case report. Pediatr Hematol Oncol 2001, 18:519-524.
34. Grainger JD, Morrell G, Yates J, et al.: Neonatal alloimmune thrombocytopenia with significant HLA antibodies. Arch Dis Child Fetal Neonatal Ed 2002, 86:F200-201.
35. Forestier F, Hohlfeld P: Management of fetal and neonatal alloimmune thrombocytopenia. Biol Neonate 1998, 74:395-401.
36. Bussel JB, Zabusky MR, Berkowitz RL, et al.: Fetal alloimmune thrombocytopenia. N Engl J Med 1997, 337:22-26.
37. Kaplan C: Alloimmune thrombocytopenia of the fetus and the newborn. Blood Rev 2002, 16:69-72.
38. Rothenberger S: Neonatal alloimmune thrombocytopenia. Ther Apher 2002, 6:32- 35.
39. Jolly MC, Letsky EA, Fisk NM: The management of fetal alloimmune thrombocytopenia. Prenat Diagn 2002, 22:96-98. • This concise, timely review of fetal alloimmune thrombocytopenia discusses published data and the experience of this condition at the authors' center. It includes a useful table summarizing the pros and cons of currently available management options.
40. Bussel JB: Alloimmune thrombocytopenia in the fetus and newborn. Semin Thromb Hemost 2001, 27:245-252.
41. Ahya R, Turner ML, Urbaniak SJ: Fetomaternal alloimmune thrombocytopenia. Transfus Apheresis Sci 2001, 25:139-145.
42. Ranasinghe E, Walton JD, Hurd CM, et al.: Provision of platelet support for fetuses and neonates affected by severe fetomaternal alloimmune thrombocytopenia. Br J Haematol 2001, 113:40-42.
43. Lee K, Beaujean F, Bierling P: Treatment of severe fetomaternal alloimmune thrombocytopenia with compatible frozen-thawed platelet concentrates. Br J Haematol 2002, 117:482-483.
44. Blanchette VS, Johnson J, Rand M: The management of alloimmune neonatal thrombocytopenia. Baillieres Clin Haematol 2000, 13:365-390.
45. Bussel J, Kaplan C: The fetal and neonatal consequences of maternal alloimmune thrombocytopenia. Baillieres Clin Haematol 1998, 11:391-408.
46. Overton TG, Duncan KR, Jolly M, et al.: Serial aggressive platelet transfusion for fetal alloimmune thrombocytopenia: platelet dynamics and perinatal outcome. Am J Obstet Gynecol 2002, 186:826-831.
47. Murphy MF, Waters AH, Doughty HA, et al.: Antenatal management of feto-maternal alloimmune thrombocytopenia - report of 15 affected pregnancies. Transfus Med 1994, 4:281-292.
48. Silver RM, Porter TF, Branch DW, et al.: Neonatal alloimmune thrombocytopenia: Antenatal management. Am J Obstet Gynecol 2000, 182:1233-1238.
49. Kaplan C, Murphy MF, Kroll H, et al.: Feto-maternal alloimmune thrombocytopenia: antenatal therapy with IvlgG and steroids-more questions than answers. European Working Group on FMAIT. Br J Haematol 1998, 100:62-65.
50. Sainio S, Teramo K, Kekomaki R: Prenatal treatment of severe fetomaternal alloimmune thrombocytopenia. Transfus Med 1999, 9:321-330.
51. Gill KK, Kelton JG: Management of idiopathic thrombocytopenic purpura in pregnancy. Semin Hematol 2000, 37:275-289.
52. Kelton JG: Idiopathic thrombocytopenic purpura complicating pregnancy. Blood Rev 2002, 16:43-46. •• This concise review, based on published evidence and first-hand experience, contains invaluable practical advice about how to manage ITP in the mother, fetus, and newborn.
53. Bussel JB: Immune thrombocytopenia in pregnancy: autoimmune and alloimmune. J Reprod Immunol 1997;37:35-61.
54. Valat AS, Caulier MT, Devos P, et al.: Relationships between severe neonatal thrombocytopenia and maternal characteristics in pregnancies associated with autoimmune thrombocytopenia. Br J Haematol 1998, 103:397-401.
55. Christiaens GC, Nieuwenhuis HK, Bussel JB: Comparison of platelet counts in first and second newborns of mothers with immune thrombocytopenic purpura. Obstet Gynecol 1997, 90:546-552.
56. Burrows RF, Kelton JG: Low fetal risks in pregnancies associated with idiopathic thrombocytopenic purpura. Am J Obstet Gynecol 1990, 163:1147-1150.
57. Ballin A, Andrew M, Ling E, et al.: High dose intravenous gammaglobulin therapy for neonatal idiopathic autoimmune thrombocytopenia. J Pediatr 1988, 112:789-792.
58. Amato M, Fauchere JC, Herman U Jr: Coagulation abnormalities in low birth weight infants with peri-intraventricular hemorrhage. Neuropediatrics 1988, 19:154-157.
59. Andrew M, Castle V, Saigal S, et al.: Clinical impact of neonatal thrombocytopenia. J Pediatr 1987, 110:457-464.
60. Van De Bor M, Briet E, Van Bel F, et al.: Hemostasis and periventricular-intraventricular hemorrhage of the newborn. Am J Dis Child 1986, 140:1131-1134.
61. Andrew M, Vegh P, Caco VC, et al.: A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. J Pediatr 1993, 123:285-291.
62. Voak D, Cann R, Finney RD, et al. Guidelines for administration of blood products: transfusion of infants and neonates. British Committee for Standards in Haematology Blood Transfusion Task Force. Transfus Med 1994, 4:63-69.
63. Roberts IAG, Murray NA: Management of thrombocytopenia in neonates. British J Haematol 1999, 105:864-870.
64. Calhoun DA, Christensen RD, Edstrom CS, et al.: Consistent approaches to procedures and practices in neonatal hematology. Clin Perinatol 2000, 27:733-753.
65. Sola MC, Calhoun DA, Hutson AD, et al.: Plasma thrombopoietin concentrations in thrombocytopenic and non-thrombocytopenic patients in a neonatal intensive care unit. Br J Haematol 1999, 104:90-92.
66. Albert TSE, Meng G, Simms P, et al.: Thrombopoietin in the thrombocytopenic term and preterm newborn. Pediatrics 2000, 105:1286-1291.
67. Murray NA, Watts TL, Roberts IAG. Endogenous thrombopoietin levels and effect of recombinant human thrombopoietin on megakaryocyte precursors in term and preterm babies. Pediatr Res 1998, 43:148-151.
68. Nishihira H, Toyoda Y, Miyazaki H, et al.: Growth of macroscopic human megakaryocyte colonies from cord blood with recombinant human thrombopoietin (c-mpl ligand) and the effects of gestational age on the frequency of colonies. Br J Haematol 1996, 92:23-28.
69. Sola MC, Du Y, Hutson AD, et al.: Dose-response relation of megakaryocyte progenitors from the bone marrow of thrombocytopenic and non-thrombocytopenic neonates to recombinant thrombopoietin. Br J Haematol 2000, 110:449-453.
70. Oygur N, Tunga M, Mumcu Y, et al.: Thrombopoietin levels of thrombocytopenic term and preterm newborns with infection. Am J Perinatol 2001, 18:279-286.
71. Li J, Yang C, Xia Y, et al.: Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001, 98:3241-3248.
72. Sola MC, Christensen RD, Hutson AD, et al.: Pharmacokinetics, pharmacodynamics, and safety of administering pegylated recombinant megakaryocyte growth and development factor to newborn rhesus monkeys. Pediatr Res 2000, 47:208-214.
73. Schwertschlag US, Trepicchio WL, Dykstra KH, et al.: Hemopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999, 13:1307-1315.
74. Chang M, Williams A, Ishizawa L, et al.: Endogenous interleukin-11 (IL-11) expression is increased and prophylactic use of exogenous IL-11 enhances platelet recovery and improves survival during thrombocytopenia associated with experimental group B sepsis in neonatal rats. Blood Cells Mol Dis 1996, 22:57-67.
75. Opal SM, Jhung JW, Keith JC Jr, et al.: Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals. J Infect Dis 1998, 178:1205-1208.
76. Opal SM, Jhung JW, Keith JC Jr, et al.: Additive effects of human recombinant interleukin-11 and granulocyte colony-stimulating factor in experimental gram-negative sepsis. Blood 1999, 93:3467-3472.
77. Claud E, Jackson M, Jilling T, et al.: Interleukin-11 diminishes intestinal injury in a rat model of necrotizing enterocolitis. Pediatr Res 2000, 47:163A.
78. Nadler EP, Stanford A, Zhang XR, et al.: Intestinal cytokine gene expression in infants with acute necrotizing enterocolitis: interleukin-11 mRNA expression inversely correlates with extent of disease. J Pediatr Surg 2001, 36:1122-1129. • This is the first paper to measure IL-11 mRNA in intestine from neonates with necrotizing enterocolitis. The RNA was extracted from intestinal segments removed at surgery from 21 neonates with necrotizing enterocolitis, 18 neonates with other acute inflammatory conditions, and 9 neonates without intestinal inflammation. Using semiquantitative RT-PCR, the authors found increased levels of IL-11 mRNA in the neonates with necrotizing enterocolitis, increased IL-11 mRNA, and decreased likelihood of pan-necrosis, suggesting that local upregulation of IL-11 might represent an adaptive response to limit the extent of intestinal damage.
79. McCloy MP, Howarth LJ, Watts TL, et al.: The role of IL-11 in neonatal thrombocytopenia. Blood 2000, 96(suppl 1):564a.
80. McCloy MP, Roberts IA, Howarth LJ, et al.: Interleukin-11 levels in healthy and thrombocytopenic neonates. Pediatr Res 2002, 51:756-760. • This is the first study to measure circulating IL-11 levels in term and preterm neonates. It establishes that plasma IL-11 is below detectable limits in normal healthy neonates and that raised plasma levels of IL-11 are strongly associated with sepsis and necrotizing enterocolitis. This suggests that IL-11 is involved in the endogenous cytokine response to sepsis and necrotizing enterocolitis in preterm neonates.